Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer

Annals of Oncology

Volumn 11, Issue 8, 2000, Pages 1023-1028

  Botwood, N ^a   James, R ^b   Vernon, C ^a   Price, P ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

'Tomudex'; Chemoradiation; Postoperative radiotherapy; Raltitrexed; Rectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; RALTITREXED;

ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LEUKOPENIA; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CANCER;

EID: 0033803267     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008376306429     Document Type: Article

References (23)

1. Cancer Statistics, 1998
2. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01
3. Prolongation of the disease-free interval in surgically treated rectal carcinoma
4. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum
5. Symposium on rectal cancer: 3. The case for adjuvant radiotherapy for rectal cancer
6. Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study
7. Time to loco-regional recurrence after resection of Dukes' B postoperative radiotherapy. A multivariate regression analysis
8. Post-operative radiation therapy for rectal cancer. An interim analysis of a prospective, randomized multicenter trial in the Netherlands
9. Effective surgical adjuvant therapy for high-risk rectal carcinoma
10. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
11. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomised, multicenter, North American trial
12. Open, randomized multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
13. Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations
14. Raltitrexed (Tomudex(TM)) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer Preliminary results from phase 1 clinical trials
15. Raltitrexed (Tomudex(TM)) in combination with platinum-based agents and/or anthracyclines: Preliminary results of phase I clinical trials
16. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)
17. Determination of the optimal dose of 5-fluorouracil when combined with low-dose D,L-leucovorin and irradiation in rectal cancer: Results of three consecutive phase II studies
18. Interaction of Tomudex with radiation in vitro and in vivo
19. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
20. Combined modality therapy of rectal cancer: Decreased acute toxicity with the preoperative approach
21. Chemoradiation with raltitrexed ('Tomudex') and concomitant preoperative radiotherapy has potential in the treatment of stage II-III resectable rectal cancer
22. Raltitrexed ('Tomudex') plus radiotherapy is well tolerated and warrants further investigation in patients with advanced inoperable/recurrent rectal cancer
23. Multidisciplinary management of resectable rectal cancer